Virbac Shares Jump 5% at Close Following Strong 2025 Results

Strong Revenue Growth in 2025

Virbac's revenue reached 1,465 million euros in 2025, with an organic growth of 7.9% on a constant scope and exchange rate basis compared to 2024. This performance exceeded the group's initial target, which aimed for growth between 5.5% and 7.5%. In the fourth quarter, growth slowed to 7.1% on a constant scope and exchange rate basis, down from 12.3% in the third quarter. All geographic areas contributed to the sales progression, notably North America with 14.7% growth and Europe with 7.5%, these two regions accounting for 54.33% of total sales. The recent acquisition of Thyronorm, a treatment for feline hyperthyroidism affecting more than 10% of older cats, generates approximately 15 million euros in annual revenue. For 2026, the veterinary laboratory anticipates revenue growth between 5.5% and 7.5% at constant exchange rates and scope.

Technical Analysis of Virbac's Stock Performance

Technically, Virbac's share price at 367 euros is above its 50-day and 200-day moving averages, set at 353.73 euros and 332.94 euros respectively. This configuration indicates a medium-term bullish trend, with the stock having risen 10.04% over three months and 19.16% over a year. The RSI at 40 remains in a neutral zone, far from the oversold threshold of 30, which leaves room before a possible consolidation. The immediate resistance is at 369 euros, very close to the current price, while the support is positioned at 338 euros. The one-month volatility is at 4.68, reflecting moderate activity. According to analysts from Oddo BHF, the recommendation remains at outperform with a price target set at 409 euros, representing a potential upside of 11.4% from the closing price.